

Rapid Case Review: Optimizing Risk Stratification and Subsequent Management of Chronic Lymphocytic Leukemia — Microlearning Activity 2

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III MAJIC trial is evaluating which regimen versus venetoclax/obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL)?
 - a. Zanubrutinib/venetoclax
 - b. Acalabrutinib/venetoclax**
 - c. Pirtobrutinib/venetoclax
 - d. Zanubrutinib/sonrotoclax
 - e. Pirtobrutinib/sonrotoclax
2. The Phase III CELESTIAL-TNCLL-2 trial is evaluating which regimen versus venetoclax/acalabrutinib for previously untreated CLL?
 - a. Zanubrutinib/venetoclax
 - b. Acalabrutinib/sonrotoclax
 - c. Pirtobrutinib/venetoclax
 - d. Zanubrutinib/sonrotoclax**
 - e. Pirtobrutinib/sonrotoclax
3. Which of the following Bruton tyrosine kinase inhibitors has shown superiority over ibrutinib in a subgroup analysis of patients with TP53-mutated, high-risk CLL from a Phase III trial?
 - a. Acalabrutinib
 - b. Zanubrutinib**
 - c. Pirtobrutinib
4. Which of the following is true regarding the ramp-up dosing associated with sonrotoclax?
 - a. Ramp-up dosing is more extensive and prolonged compared to venetoclax
 - b. Multiple ramp-up dosing strategies are under investigation**
 - c. Ramp-up dosing is not necessary with sonrotoclax